Evidence-Based Reviews

Cognitive-behavioral therapy for insomnia: A review of 8 studies

Author and Disclosure Information

 

References

The prevalence of insomnia in the general population is approximately 6% to 10%.1 In addition, an estimated 30% of the general population may have symptoms of insomnia without meeting the diagnostic criteria.2 As a disorder, insomnia is characterized by a persistent difficulty initiating or maintaining sleep, or early morning awakening with inability to return to sleep, that has been present for at least 3 months. Additionally, the sleep difficulties must occur at least 3 nights a week, result in impaired daytime functioning, and cause significant distress.1

Cognitive-behavioral therapy for insomnia (CBT-I) is an effective treatment, supported by several systematic reviews and meta-analyses.3-5 In the short term, CBT-I is as effective as pharmacotherapy.6 However, CBT-I is the preferred treatment for chronic insomnia, according to recommendations in European and American guidelines.7,8

Here we review 8 recent studies that examined CBT-I. These studies are summarized in the Table.9-16

Cognitive-behavioral therapy for insomnia: 8 Studies

1. Cheng P, Kalmbach DA, Tallent G, et al. Depression prevention via digital cognitive behavioral therapy for insomnia: a randomized controlled trial. Sleep. 2019;42(10):zsz150. doi: 10.1093/sleep/zsz150.

Although CBT-I is a first-line treatment for chronic insomnia, it is underutilized in clinical practice primarily due to limited availability. Because few clinicians are certified in CBT-I, it has become necessary to develop alternative modes of delivery for CBT-I, such as fully automated, internet-delivered approaches to reach more patients with insomnia. Digital CBT-I (dCBT-I) is comparable to in-person CBT-I in improving insomnia symptoms and reducing concurrent depressive symptoms with insomnia. It is unclear if unguided, internet-delivered CBT-I is effective for achieving remission from depression or preventing depression in the long term. Chen et al9 examined the efficacy of dCBT-I in reducing and preventing depression over a 1-year follow-up.

Study design

  • Participants from various centers in Southeastern Michigan were recruited between 2016 and 2017. Data was obtained from the Sleep to Prevent Evolving Affective Disorders (SPREAD) trial.
  • Participants who met DSM-5 criteria for chronic insomnia disorder were randomized to dCBT-I (n = 358) using the Sleepio digital CBT program via the internet or to online sleep education (n = 300).
  • The primary outcome was depression, measured using the Quick Inventory of Depressive Symptomatology-Self Report (QIDS-SR-16) at 1-year follow-up. Depression incidence was also tested against insomnia treatment response.

Outcomes

  • The severity of depression was significantly lower at 1-year follow-up in the dCBT-I group compared with the control group.
  • The dCBT-I group showed a 51% higher remission rate than the control group at 1-year follow-up.
  • The incidence of moderate to severe depression in individuals with minimal to no depression at baseline was halved at 1 year after receiving dCBT-I treatment compared with the control group.

Continue to: Conclusion

Pages

Recommended Reading

Sleep quality may affect COPD risk in African American smokers
MDedge Psychiatry
COVID-19: Delirium first, depression, anxiety, insomnia later?
MDedge Psychiatry
Less REM sleep tied to higher mortality
MDedge Psychiatry
FDA approves low-sodium treatment option for narcolepsy
MDedge Psychiatry
Pandemic-related stress causing health issues in many Americans
MDedge Psychiatry
Patients with COPD plus sleep problems should be screened for mood disorders
MDedge Psychiatry
‘Long sleep’ or apnea in middle age double risk for Alzheimer’s disease
MDedge Psychiatry
Sleep problems in young children linked to lower QOL in later years
MDedge Psychiatry
Clinical pearls for administering cognitive exams during the pandemic
MDedge Psychiatry
Alzheimer’s disease may affect sleep patterns
MDedge Psychiatry